When it comes to life sciences manufacturing, there's nothing quite so daunting as a tech transfer - moving a product from development to commercialisation, or to a new facility or CDMO, pr
Following her attendance at DIA Europe 2024, Humaira Qureshi from Qinecsa Solutions, discusses the historic challenges of pharmacovigilance and embracing a new future-ready ecosystem.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh